Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6312957

Title:Genetic modification of primate hemopoietic repopulating stem cells
Inventors:Einerhand, Markus Peter Wilhelmus; Amsterdam, Netherlands
Summary:This invention describes the transfection of primate pluripotent hematopoietic stem cells with an adeno-associated viral vector, methods and uses thereof. Described herein is the genetic modification of pluripotent hemopoietic stem cells of primates (P-PHSC) by transduction of the P-PHSCs with a recombinant adeno-associated virus (AAV). Claims of the invention include a tile genome of the recombinant AAV comprised of a DNA sequence flanked by the inverted terminal repeats (ITR) of AAV, such that the DNA sequence consists of regulatory sequences which are functional in hemopoietic cells and a sequence coding for a protein or RNA with a therapeutic property when introduced into hemopoietic cells. Further disclosed are the means by which such DNA sequences are the human lysosomal glococerebrosidase gene, a globin gene from the human beta-globin gene cluster, a DNA sequence encoding an RNA or protein with anti-viral activity, the alpha1-antitrypsin gene and the human multidrug resistance gene I (MDRI). Human therapeutic applications include the treatment of diseases such as sickle cell anaemia.
Abstract:Genetic modification of pluripotent hemopoietic stem cells of primates (P-PHSC) by transduction of P-PHSC with a recombinant adeno-associated virus (AAV). Tile genomc of the recombinant AAV comprises a DNA sequence flanked by the inverted terminal repeats (ITR) of AAV. The DNA sequence will normally comprise regulatory sequences which are functional in hemopoictic cells and, controlled by these regulatory sequences, a sequence coding for a protein or RNA with a therapeutic property when introduced into hemopoietic cells. Preferred examples of DNA sequences are the human lysosomal glococerebrosidase gene, a globin gene from the human .beta.-globin gene cluster, a DNA sequence encoding an RNA or protein with anti-viral activity, the .alpha.1-antitrypsin gene and the human multidrug resistance gene I (MDRI). The invention provides for effective gene therapy with PHSC of primates, in particular humans.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6312957
Application Number:US1999000326032
Date Filed:04/06/1999
Date Published:06/11/2001
Assignee:Introgene B.V. Netherlands


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021